Furthermore, BB-tau and BB-p-tau were shown to be useful biomarkers for progression to cognitive decline, for predicting progression to AD or for diagnosing AD [3, 7, 13, 15, 20–22, 26, 30, 31, 34, 38, 47, 57, 60]. This evidence concerns the gene MAPT and Alzheimer disease.